NexgenRxNEGXF 51 Days Payable is 181.66 as of Mar. 2026, which is 12% below its 10-year median of 205.64. GuruFocus rates NEGXF with a GF Score™ of 51/100 and a GF Value™ of $0.27 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 607 Healthcare Providers & Services companies, NexgenRx ranks better than 69.69% on this metric.
NexgenRx's average Accounts Payable for the
three
months ended in Mar. 2026 was $1.08 Mil. NexgenRx's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $0.54 Mil.
Hence, NexgenRx's Days Payable for the
three
months ended in Mar. 2026 was 181.66.
The historical rank and industry rank for NexgenRx's Days Payable or its related term are showing as below:
NEGXF'
s Days Payable Range Over the Past 10 Years
Min: 91.77 Med: 205.64 Max: 350.23
Current: 100.48
During the past 13 years, NexgenRx's highest Days Payable was 350.23. The lowest was 91.77. And the median was 205.64.
NEGXF's Days Payable is ranked better than 69.69% of 607
companies
in the Healthcare Providers & Services industry
Industry Median: 58
vs NEGXF: 100.48
NexgenRx's Days Payable
increased
from Mar. 2025 (35.35) to Mar. 2026 (181.66).
It may suggest that NexgenRxdelayed paying its suppliers.
NexgenRx Days Payable Related Terms
NexgenRx Days Payable Historical Data
* Premium members only.
The historical data trend for NexgenRx's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, NexgenRx's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NexgenRx Days Payable vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, NexgenRx's Days Payable distribution charts can be found below:
* The bar in red indicates where NexgenRx's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
NexgenRx's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NexgenRx (NEGXF) has a Days Payable of 181.66 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on NexgenRx and its competitors. This is 12% below median its historical median of 205.64. Over the past decade, NexgenRx's Days Payable has ranged from 91.77 to 350.23. According to the industry distribution chart, NexgenRx ranks #184 out of 607 companies in the Healthcare Providers & Services industry, placing it in the top 30.3%.
Is NexgenRx's Days Payable too high?
NexgenRx's current Days Payable of 181.66 is 12% below median its 10-year median of 205.64. Over the past 10 years, this metric has ranged from a low of 91.77 to a high of 350.23. The Healthcare Providers & Services industry median Days Payable is 58.00. NexgenRx's value of 181.66 is 213.2% above this industry median. Based on the distribution chart, NexgenRx ranks #184 out of 607 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, NexgenRx has a GF Score™ of 51/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NexgenRx's Days Payable compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, NexgenRx ranks #184 out of 607 companies for Days Payable. This puts NexgenRx in the upper half of its industry. The industry median Days Payable is 58.00. NexgenRx's value of 181.66 is 213.2% above this benchmark. Historically, NexgenRx's own Days Payable has ranged from 91.77 to 350.23 over the past decade. While the company's 10-year median is 205.64 vs. the industry median of 58.00, NexgenRx has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Healthcare Providers & Services company?
The median Days Payable among Healthcare Providers & Services companies is 58.00, based on 607 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NexgenRx's current Days Payable of 181.66 is 213.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on NexgenRx and its competitors. For the Healthcare Providers & Services industry, the median Days Payable is 58.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NexgenRx's current Days Payable is 181.66, which is 12% below median its own 10-year median of 205.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NexgenRx stock overvalued right now?
Based on GuruFocus' analysis, NexgenRx (NEGXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.27, compared to a current price of $0.33 — trading 20.4% above its estimated fair value. The current Days Payable is 181.66, which is 12% below median its 10-year median of 205.64 and 213.2% above the Healthcare Providers & Services industry median of 58.00. NexgenRx's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For NexgenRx (NEGXF), the current Days Payable is 181.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NexgenRx (NEGXF) Overvalued in 2026?
Based on GuruFocus' analysis, NexgenRx stock appears to be overvalued.
The current stock price of $0.33 is trading 20.4% above its estimated GF Value™ of $0.27.
GuruFocus considers NexgenRx to be Modestly Overvalued.
Key valuation signals for NEGXF:
Days Payable: 181.66 (12% below median its 10-year median of 205.64)
GF Value™: $0.27 vs. price of $0.33 (20.4% above fair value)
Industry Position: 213.2% above the Healthcare Providers & Services median (#184 of 607)
No single metric tells the full story. See the NEGXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NexgenRx Inc administers, adjudicates, and pays drug, dental and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers using proprietary computer software and also provides ancillary services. The various solutions offered by the company include: NexSys, a fully integrated rules-based adjudication platform for real-time processing of drug, dental, and extended health benefit claims; NexAdmin, which enables sponsors to take complete control of benefit plan administration; and NexPSPAssist, a service that helps Patient Support Programs (PSP) to optimize their deliverables to their manufacturer clients. The company has only one operating segment - benefits administration services.
51GF Score
Get the complete analysis for NEGXF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NEGXF has been successfully added to your 
